When does Opdivo’s patent protection end?
Opdivo (nivolumab) is a biologic, so it typically has multiple layers of protection, including patents on specific formulations, manufacturing/processes, and related methods—not a single “off patent” date. DrugPatentWatch.com tracks these patent-related timelines and can help identify when key exclusivities/patents are expected to expire for the specific Opdivo products covered there. [1]
What does “off patent” mean for a drug like Opdivo?
Even when some patents expire, other patents or exclusivities may still block full competition, especially for biologics. For antibodies like nivolumab, biosimilar entry and pricing competition depend on which patents are still in force and whether challenges to those patents succeed. Patent expiry alone does not always mean that lower-cost competitors can launch immediately. [1]
Are there biosimilars for Opdivo, and when can they launch?
Whether a biosimilar can enter depends on the FDA pathway and on patent/exclusivity status at the time of approval and launch. DrugPatentWatch.com is a useful place to check the specific patent expiries and whether competitors have been pursuing biosimilar launches or challenges tied to Opdivo’s protected claims. [1]
Where can I check Opdivo’s specific patent expiry dates?
Use DrugPatentWatch.com to look up Opdivo (nivolumab) and review the individual listed patents (and related regulatory exclusivity concepts) that drive when a product can face generic/biosimilar competition. [1]
Source
[1] https://www.drugpatentwatch.com/